Compare KFRC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFRC | NMRA |
|---|---|---|
| Founded | 1962 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.6M | 424.4M |
| IPO Year | 1995 | 2023 |
| Metric | KFRC | NMRA |
|---|---|---|
| Price | $30.96 | $1.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $34.75 | $8.00 |
| AVG Volume (30 Days) | 251.2K | ★ 946.8K |
| Earning Date | 02-02-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $1,340,771,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.49 | $0.61 |
| 52 Week High | $57.60 | $11.57 |
| Indicator | KFRC | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 37.78 |
| Support Level | $30.37 | $1.69 |
| Resistance Level | $31.75 | $1.93 |
| Average True Range (ATR) | 0.98 | 0.12 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 65.09 | 20.97 |
Kforce Inc is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. The company operates two business segments: 1) In technology segment it provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. 2) In FA segment company offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting business and cost analysis; and taxation and treasury. The majority of revenue is earned through the technology segment.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.